Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16587378 | 0.87 | MEN1 (0.59) | ALDH1A1LMNAGAAMAPTPOLB | |
| SCHEMBL14192474 | 0.83 | MEN1 (0.59) | ALDH1A1LMNAGAAMAPTPOLB | |
| SCHEMBL10202342 | 0.83 | TDP1 (0.55) | ALDH1A1LMNAGAAPOLBTDP1 | |
| SCHEMBL14817549 | 0.81 | ALDH1A1 (0.61) | ALDH1A1LMNAGAAMAPTPOLB | |
| SCHEMBL699925 | 0.80 | MEN1 (0.71) | ALDH1A1LMNAGAAMEN1KMT2A | |
| SCHEMBL10172594 | 0.79 | ALDH1A1 (0.58) | ALDH1A1LMNAGAAMAPTPOLB | |
| SCHEMBL171909 | 0.79 | CRHBP (0.58) | ALDH1A1LMNAGAAMAPTPOLB | |
| SCHEMBL10866850 | 0.78 | ALDH1A1 (0.66) | ALDH1A1LMNAGAAMAPTPOLB | |
| SCHEMBL3565748 | 0.78 | ALDH1A1 (0.57) | ALDH1A1LMNAGAAMAPTPOLB | |
| SCHEMBL13664094 | 0.77 | ALDH1A1 (0.56) | ALDH1A1LMNAGAAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371473-B2 | Accelerators for two step adhesive systems | Henkel IP & Holding GmbH (DE) | 2016-06-21 | — | — | US | disclosed |
| US-9365750-B2 | Accelerators for curable compositions | Henkel IP & Holding GmbH (DE) | 2016-06-14 | — | — | US | disclosed |
| US-8986847-B2 | Accelerator/oxidant/proton source combinations for two part curable compositions | Henkel IP & Holding GmbH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | ALDH1A1 3139/4885LMNA 4752/4885GAA 764/4885 |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | ALDH1A1 3139/4885LMNA 4752/4885GAA 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.